Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Debt to Equity (2021 - 2025)

Bioregenx has reported Debt to Equity over the past 5 years, most recently at -$0.26 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 22.44% year-over-year to -$0.26; the TTM value through Dec 2025 reached -$0.26, up 22.44%, while the annual FY2025 figure was -$0.26, 22.44% up from the prior year.
  • Debt to Equity for Q4 2025 was -$0.26 at Bioregenx, up from -$0.62 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.14 in Q2 2024 and troughed at -$2.37 in Q4 2021.
  • A 5-year average of -$0.37 and a median of -$0.17 in 2025 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: surged 277.04% in 2024 and later tumbled 956.46% in 2025.
  • Year by year, Debt to Equity stood at -$2.37 in 2021, then skyrocketed by 96.67% to -$0.08 in 2022, then plummeted by 450.0% to -$0.44 in 2023, then rose by 22.62% to -$0.34 in 2024, then rose by 22.44% to -$0.26 in 2025.
  • Business Quant data shows Debt to Equity for BRGX at -$0.26 in Q4 2025, -$0.62 in Q3 2025, and -$0.58 in Q2 2025.